Filing Flows › Comparisons › CSTL vs FLGT
Castle Biosciences vs Fulgent Genetics: CSTL and FLGT compared
Castle Biosciences is the larger company: $103M of revenue in its latest quarter (Q3 2026) against $90.4M for Fulgent Genetics (Q3 2026). Castle Biosciences is growing faster (+24% against +8% a year earlier). Castle Biosciences is more profitable, with an operating margin of -2.7% against -24.9%.
Where the money goes: CSTL and FLGT
Castle Biosciences (CSTL) · Q3 2026
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Fulgent Genetics (FLGT) · Q3 2026
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
| Castle Biosciences (CSTL) | Fulgent Genetics (FLGT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $103M | $90.4M |
| Revenue growth, Y/Y | +24% | +8% |
| Operating margin | -2.7% | -24.9% |
| Net earnings | −$4.1M | −$13.3M |
| Net margin | -4.0% | -14.8% |
| Operating cash flow | $19.7M | $109M |
| Free cash flow | $12.2M | $107M |
Where the revenue comes from
Castle Biosciences
- Non-Dermatologic: $55.0M (53%)
- Dermatologic: $47.9M (47%)
Questions
Which is bigger, Castle Biosciences or Fulgent Genetics?
Castle Biosciences is the larger company: $103M of revenue in its latest quarter (Q3 2026) against $90.4M for Fulgent Genetics (Q3 2026).
Is Castle Biosciences or Fulgent Genetics growing faster?
Castle Biosciences is growing faster (+24% against +8% a year earlier).
Which is more profitable, Castle Biosciences or Fulgent Genetics?
Castle Biosciences is more profitable, with an operating margin of -2.7% against -24.9%.
More: Castle Biosciences earnings · how Castle Biosciences makes money · Fulgent Genetics earnings · how Fulgent Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.